Jun 22, 2009 - Kowa Pharmaceuticals America, Inc., a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. FDA) has approved Cambia™, a diclofenac-based non-steroidal anti-inflammatory drug combined with potassium bicarbonate, for the treatment of acute migraine with or without aura in adults.
The details can be read here.
No comments:
Post a Comment